• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性乳腺癌中浸润肿瘤前沿和肿瘤中心的肿瘤浸润免疫细胞的不同模式与新辅助化疗的反应相关。

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.

机构信息

Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Institute for Pathology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

出版信息

BMC Cancer. 2019 Feb 4;19(1):120. doi: 10.1186/s12885-019-5320-2.

DOI:10.1186/s12885-019-5320-2
PMID:30717704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6360695/
Abstract

BACKGROUND

Tumor-infiltrating lymphocytes (TILs) are described as an important immune modulator in the tumor microenvironment and are associated with breast cancer (BC) outcome. The spatial analysis of TILs and TIL subtype distribution at the invasive tumor front (ITF) and the tumor center (TC) might provide further insights into tumor progression.

METHODS

We analyzed core biopsies from 87 pre-therapeutic BC patients for total TILs and the following subtypes: CD3+, CD4+, CD8+, CD20+ and CD68+ cells in correlation to clinicopathological parameters and disseminated tumor cells (DTCs) in the bone marrow.

RESULTS

TILs and TIL subtypes showed significantly different spatial distribution among both tumor areas. TILs, especially CD3+ T cells were associated with the tumor status and tumor grading. BC patients responding to neoadjuvant chemotherapy had significantly more TILs and CD3+ T cells at the TC. The presence of DTCs after NACT was related to CD4+ infiltration at the TC.

CONCLUSION

The dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.

摘要

背景

肿瘤浸润淋巴细胞(TILs)被描述为肿瘤微环境中的一种重要免疫调节剂,与乳腺癌(BC)的结局相关。在浸润性肿瘤前沿(ITF)和肿瘤中心(TC)对 TILs 及其亚型分布进行空间分析,可能有助于进一步了解肿瘤的进展。

方法

我们分析了 87 例接受新辅助化疗前 BC 患者的核心活检标本,以评估总 TILs 及以下亚型:CD3+、CD4+、CD8+、CD20+和 CD68+细胞,同时分析了骨髓中的弥散性肿瘤细胞(DTCs)。

结果

TILs 和 TIL 亚型在肿瘤区域之间的空间分布存在显著差异。TILs,尤其是 CD3+T 细胞与肿瘤状态和肿瘤分级相关。对新辅助化疗有反应的 BC 患者在 TC 处有更多的 TILs 和 CD3+T 细胞。NACT 后存在 DTCs 与 TC 处的 CD4+浸润有关。

结论

TILs 和 TIL 亚型与临床病理参数、NACT 反应和微小残留病的不同空间关联,强调了对免疫调节过程进行详细 TIL 分析的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/6360695/5f8b8a54593e/12885_2019_5320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/6360695/d5559ee474c8/12885_2019_5320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/6360695/5f8b8a54593e/12885_2019_5320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/6360695/d5559ee474c8/12885_2019_5320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/6360695/5f8b8a54593e/12885_2019_5320_Fig2_HTML.jpg

相似文献

1
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.原发性乳腺癌中浸润肿瘤前沿和肿瘤中心的肿瘤浸润免疫细胞的不同模式与新辅助化疗的反应相关。
BMC Cancer. 2019 Feb 4;19(1):120. doi: 10.1186/s12885-019-5320-2.
2
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.肿瘤浸润淋巴细胞(TILs)的形态学评估以研究浸润性乳腺癌的免疫原性、揭示淋巴细胞网络并辅助复发预测:一项回顾性研究
Int J Mol Sci. 2017 Sep 8;18(9):1936. doi: 10.3390/ijms18091936.
3
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.新辅助化疗后基质淋巴细胞浸润与 HER2 阳性乳腺癌侵袭性残留疾病和无病生存率降低相关。
Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.
4
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.新辅助化疗治疗的乳腺癌患者治疗前后分子亚型与基质免疫浸润的相互作用。
Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12.
5
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.乳腺癌中的肿瘤浸润淋巴细胞可预测化疗反应和生存结果:一项荟萃分析。
Oncotarget. 2016 Jul 12;7(28):44288-44298. doi: 10.18632/oncotarget.9988.
6
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.原发性全身化疗后丰富的肿瘤浸润淋巴细胞预示着雌激素受体阳性/HER2 阴性乳腺癌预后不良。
Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22.
7
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系:新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
8
Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.新辅助化疗后三阴性乳腺癌的残余肿瘤负荷指数和肿瘤浸润淋巴细胞亚群。
Breast Cancer Res Treat. 2020 Jan;179(1):11-23. doi: 10.1007/s10549-019-05437-z. Epub 2019 Sep 16.
9
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.肿瘤浸润免疫细胞谱及其在新辅助化疗后的变化可预测乳腺癌的反应和预后。
Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5.
10
Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).基于肿瘤间质纤维灶内肿瘤浸润淋巴细胞(FF-TILs)预测乳腺癌新辅助化疗(NAC)后的结局
Anticancer Res. 2022 Mar;42(3):1421-1431. doi: 10.21873/anticanres.15612.

引用本文的文献

1
Double-Multiplex Immunostainings for Immune Profiling of Invasive Breast Carcinoma: Emerging Novel Immune-Based Biomarkers.用于浸润性乳腺癌免疫谱分析的双重多重免疫染色:新兴的基于免疫的新型生物标志物
Int J Mol Sci. 2025 Mar 21;26(7):2838. doi: 10.3390/ijms26072838.
2
CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.乳腺癌中CD3 +肿瘤浸润淋巴细胞:其预后作用及与临床参数的关联
Cureus. 2024 Dec 10;16(12):e75479. doi: 10.7759/cureus.75479. eCollection 2024 Dec.
3
Identification of the novel exhausted T cell CD8 + markers in breast cancer.

本文引用的文献

1
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
2
Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells.骨髓播散肿瘤细胞免疫荧光检测的优化
Biol Proced Online. 2018 Jul 1;20:13. doi: 10.1186/s12575-018-0078-5. eCollection 2018.
3
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
鉴定乳腺癌中新型耗竭 T 细胞 CD8+标志物。
Sci Rep. 2024 Aug 19;14(1):19142. doi: 10.1038/s41598-024-70184-1.
4
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.新辅助化疗联合双重HER2阻断治疗的HER2阳性乳腺癌中的肿瘤浸润淋巴细胞
NPJ Breast Cancer. 2024 Apr 18;10(1):29. doi: 10.1038/s41523-024-00636-4.
5
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.基于图像的癌症组织多重免疫分析:转化意义。国际乳腺癌免疫肿瘤学生物标志物工作组报告。
J Pathol. 2024 Mar;262(3):271-288. doi: 10.1002/path.6238. Epub 2024 Jan 17.
6
Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.揭示乳腺癌免疫微环境的作用:窥探充满希望的前沿领域。
Int J Mol Sci. 2023 Oct 18;24(20):15332. doi: 10.3390/ijms242015332.
7
Assay-agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple-negative breast cancer.无分析物检测的空间蛋白质组分析检测肿瘤微环境特征:三阴性乳腺癌的新诊断见解。
Mol Oncol. 2023 Oct;17(10):1953-1961. doi: 10.1002/1878-0261.13515. Epub 2023 Sep 11.
8
Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy.空间免疫表型在新辅助化疗后米勒-佩恩4级三阴性乳腺癌中影响预后。
NPJ Breast Cancer. 2023 Jul 12;9(1):57. doi: 10.1038/s41523-023-00565-8.
9
Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics.肯尼亚乳腺癌患者的肿瘤浸润淋巴细胞(TILs)和免疫组成:空间分布及与危险因素和肿瘤特征的关联。
Breast Cancer Res Treat. 2023 Jun;199(2):401-413. doi: 10.1007/s10549-023-06921-3. Epub 2023 Apr 3.
10
Microfluidics guided by deep learning for cancer immunotherapy screening.基于深度学习的癌症免疫疗法筛选的微流控技术。
Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2214569119. doi: 10.1073/pnas.2214569119. Epub 2022 Nov 7.
浸润淋巴细胞与不同亚型乳腺癌患者预后的关系:新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
4
Disseminated breast tumour cells: biological and clinical meaning.播散性乳腺肿瘤细胞:生物学及临床意义
Nat Rev Clin Oncol. 2018 Mar;15(3):129-131. doi: 10.1038/nrclinonc.2017.174. Epub 2017 Nov 21.
5
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.评估实体瘤中的肿瘤浸润淋巴细胞:病理学家实用综述及国际免疫肿瘤生物标志物工作组提出的标准化方法建议:第 1 部分:评估宿主免疫反应、浸润性乳腺癌及导管原位癌中的肿瘤浸润淋巴细胞、转移性肿瘤沉积及进一步研究领域。
Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162.
6
The association of tumor lymphocyte infiltration with clinicopathological factors and survival in breast cancer.肿瘤淋巴细胞浸润与乳腺癌临床病理因素及生存情况的相关性
Pol J Pathol. 2017;68(1):26-32. doi: 10.5114/pjp.2017.67612.
7
Targeted therapies in breast cancer: New challenges to fight against resistance.乳腺癌的靶向治疗:对抗耐药性的新挑战
World J Clin Oncol. 2017 Apr 10;8(2):120-134. doi: 10.5306/wjco.v8.i2.120.
8
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.肿瘤浸润淋巴细胞与乳腺癌:超越预后和预测效用
Tumour Biol. 2017 Apr;39(4):1010428317695023. doi: 10.1177/1010428317695023.
9
Breast Cancer Immunotherapy.乳腺癌免疫疗法
Maedica (Bucur). 2015 Jun;10(2):185-191.
10
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.